Compile Data Set for Download or QSAR
Report error Found 102 Enz. Inhib. hit(s) with Target = 'Catenin beta-1/B-cell CLL/lymphoma 9 protein'
TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712841(US20250019371, Compound 26)
Affinity DataIC50: 5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571672(CHEMBL4865480 | US20250019371, Compound 28)
Affinity DataIC50: 5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571673(CHEMBL4871518 | US20250019371, Compound 29)
Affinity DataIC50: 5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571674(CHEMBL4867597 | US20250019371, Compound 30)
Affinity DataIC50: 5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571665(CHEMBL4853758 | US20250019371, Compound 21)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571666(CHEMBL4876302 | US20250019371, Compound 22)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571667(CHEMBL4859967 | US20250019371, Compound 23)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712839(US20250019371, Compound 24)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712840(US20250019371, Compound 25)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571671(CHEMBL4873369 | US20250019371, Compound 27)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712851(US20250019371, Compound 35)
Affinity DataIC50: 1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571662(CHEMBL4875573 | US20250019371, Compound 18)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571663(CHEMBL4855866 | US20250019371, Compound 19)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571664(CHEMBL4866328 | US20250019371, Compound 20)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712848(US20250019371, Compound 32)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712849(US20250019371, Compound 33)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712850(US20250019371, Compound 34)
Affinity DataIC50: 3.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571660(CHEMBL4863752 | US20250019371, Compound 16)
Affinity DataIC50: 1.00E+5nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571661(CHEMBL4861802 | US20250019371, Compound 17)
Affinity DataIC50: 1.00E+5nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712847(US20250019371, Compound 31)
Affinity DataIC50: 2.00E+5nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM652137(US11905273, Example 2)
Affinity DataKi:  2.20E+3nMAssay Description:All experiments were performed in shite opaque 384-well plates from PerkinElmer (Waltham, MA) with an assay buffer of 25 mM HEPES (pH=7.4), 100 Mm nA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM652140(US11905273, Example 5)
Affinity DataKi:  4.20E+3nMAssay Description:All experiments were performed in shite opaque 384-well plates from PerkinElmer (Waltham, MA) with an assay buffer of 25 mM HEPES (pH=7.4), 100 Mm nA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571666(CHEMBL4876302 | US20250019371, Compound 22)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571667(CHEMBL4859967 | US20250019371, Compound 23)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712841(US20250019371, Compound 26)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571671(CHEMBL4873369 | US20250019371, Compound 27)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571672(CHEMBL4865480 | US20250019371, Compound 28)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571673(CHEMBL4871518 | US20250019371, Compound 29)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571674(CHEMBL4867597 | US20250019371, Compound 30)
Affinity DataKi: <5.00E+3nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM588192((S)-(4-(3-Cyclohexyl-4-(pyrrolidin-3- yloxy)benzoy...)
Affinity DataKi:  5.20E+3nMAssay Description:Alphascreen Assays to Determine the Apparent Kd Values for Wild-Type and Mutant β-Catenin/BCL9 InteractionsThe experimental detail using AlphaSc...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50501080(CHEMBL3819506 | US12286422, Example 10)
Affinity DataKi:  5.20E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM588210(US11542254, Example canosic acid | US12286422, Exa...)
Affinity DataKi:  5.30E+3nMAssay Description:Alphascreen Assays to Determine the Apparent Kd Values for Wild-Type and Mutant β-Catenin/BCL9 InteractionsThe experimental detail using AlphaSc...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM588210(US11542254, Example canosic acid | US12286422, Exa...)
Affinity DataKi:  5.30E+3nMMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM652139(US11905273, Example 4)
Affinity DataKi:  7.10E+3nMAssay Description:All experiments were performed in shite opaque 384-well plates from PerkinElmer (Waltham, MA) with an assay buffer of 25 mM HEPES (pH=7.4), 100 Mm nA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM652102(US11905273, Example 1)
Affinity DataKi:  8.00E+3nMAssay Description:All experiments were performed in shite opaque 384-well plates from PerkinElmer (Waltham, MA) with an assay buffer of 25 mM HEPES (pH=7.4), 100 Mm nA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM588205(4-(3-((S)-3-Ethyl-4-(4'-fluoro-6- (((S)-pyrrolidin...)
Affinity DataKi:  1.00E+4nMAssay Description:Alphascreen Assays to Determine the Apparent Kd Values for Wild-Type and Mutant β-Catenin/BCL9 InteractionsThe experimental detail using AlphaSc...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50571665(CHEMBL4853758 | US20250019371, Compound 21)
Affinity DataKi: <1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712839(US20250019371, Compound 24)
Affinity DataKi: <1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712840(US20250019371, Compound 25)
Affinity DataKi: <1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM712851(US20250019371, Compound 35)
Affinity DataKi: <1.00E+4nMAssay Description:The β-catenin/BCL9 protein-protein interaction (PPI) has emerged as a potential therapeutic target to suppress the hyperactive Wnt/β-catenin signalin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM736147(4-(3-((S)-3-Ethyl-4-(4'-fluoro-6- (((S)-pyrrolidin...)
Affinity DataKi:  1.00E+4nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM588209((S)-1-(3-Fluoro-5-(4-(4-(pyrrolidin- 3-yloxy)-3-(4...)
Affinity DataKi:  1.40E+4nMAssay Description:Alphascreen Assays to Determine the Apparent Kd Values for Wild-Type and Mutant β-Catenin/BCL9 InteractionsThe experimental detail using AlphaSc...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM652138(US11905273, Example 3)
Affinity DataKi:  1.40E+4nMAssay Description:All experiments were performed in shite opaque 384-well plates from PerkinElmer (Waltham, MA) with an assay buffer of 25 mM HEPES (pH=7.4), 100 Mm nA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM736151((S)-1-(3-Fluoro-5-(4-(4-(pyrrolidin- 3-yloxy)-3-(4...)
Affinity DataKi:  1.40E+4nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM588194((S)-(4-(3-Fluoro-5-(piperazin-1-yl) methylcyclohex...)
Affinity DataKi:  1.60E+4nMAssay Description:Alphascreen Assays to Determine the Apparent Kd Values for Wild-Type and Mutant β-Catenin/BCL9 InteractionsThe experimental detail using AlphaSc...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50501081(CHEMBL3819020 | US12286422, Example 12)
Affinity DataKi:  1.60E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM588184(S)-(4-(3-Fluoro-5-(piperazin-1-yl) benzoyl)piperaz...)
Affinity DataKi:  1.90E+4nMAssay Description:Alphascreen Assays to Determine the Apparent Kd Values for Wild-Type and Mutant β-Catenin/BCL9 InteractionsThe experimental detail using AlphaSc...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM689285(S)-(4-(3-Fluoro-5-(piperazin-1-yl) benzoyl)piperaz...)
Affinity DataKi:  1.90E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM588184(S)-(4-(3-Fluoro-5-(piperazin-1-yl) benzoyl)piperaz...)
Affinity DataKi:  2.00E+4nMAssay Description:Alphascreen Assays to Determine the Apparent Kd Values for Wild-Type and Mutant β-Catenin/BCL9 InteractionsThe experimental detail using AlphaSc...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetCatenin beta-1/B-cell CLL/lymphoma 9 protein(Human)
H. Lee Moffitt Cancer Center and Research Institute

US Patent
LigandPNGBDBM50501086(CHEMBL3818707 | US12286422, Example 8)
Affinity DataKi:  2.00E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 102 total ) | Next | Last >>
Jump to: